Anti-CD20 patent battle ends
نویسندگان
چکیده
منابع مشابه
Ofatumumab: a novel monoclonal anti-CD20 antibody
Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC). Pha...
متن کاملAnti-CD20: tales of identical twins?
atomic resolution structural information is X-ray crystallography, a technique accounting for 88% of structures deposited in the Protein Data Bank. Unfortunately, this technique requires milligram amounts of purified protein , which has to subsequently be induced to form crystals. Both protein production and crystallization can be difficult tasks particularly for membrane-bound, multidomain and...
متن کاملTITLE: Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Running title: CD20 mechanisms
word count: 194 Scientific Heading: Neoplasia Copyright (c) 2003 American Society of Hematology Blood First Edition Paper, prepublished online October 9, 2003; DOI 10.1182/blood-2003-06-2031 For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
متن کاملSurface Levels of CD20 Determine Anti-CD20 Antibodies Mediated Cell Death In Vitro
BACKGROUND The sensitivity of human Burkitt's lymphoma cells to rituximab (Rtx) and tositumomab (Tst) was assessed on cells expressing different levels of CD20 on surface. Cells that harbor low CD20 levels may resists against therapeutics response to CD20-specific antibodies. We postulated that, radiation-induced modulation of CD20 surface levels may play a crucial and central role in determini...
متن کاملTargeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.
Rituximab (chimeric anti-CD20 monoclonal antibody) is widely employed in the treatment of patients with B cell non-Hodgkin lymphoma (NHL). This agent has activity in both indolent and aggressive disease, alone and in combination with chemotherapy. Unfortunately, however, many patients develop resistant disease. Ongoing efforts to improve outcomes include changes in dose and schedule, as well as...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 2010
ISSN: 1087-0156,1546-1696
DOI: 10.1038/nbt0810-769b